In December 2014, Pfizer and OPKO began an agreement to develop hGH-CTP for growth hormone deficiency in adults and children, and for children who are small for gestational age and fail to show ...

Pfizer already makes big revenues ... iDFS than hormone therapy alone in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early-stage breast cancer.

Pfizer PFE has been relying on its newly launched ... a long-acting once-weekly treatment for pediatric growth hormone deficiency. Litfulo was approved in Europe in September 2023, Elrexfio ...

The pharma giant delivered mixed Q2 results, with strong growth from its acquisition-enhanced oncology business, but headwinds from declining COVID-19 vaccine sales. Pfizer boosted its full-year ...

Pfizer and Arvinas’ estrogen receptor (ER ... The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast ...

Pfizer said Tuesday. The company also cited sales growth from several other drugs, as total revenue climbed 31% to $17.7 billion in the recently completed quarter. Adjusted earnings totaled $1.06 ...

March 11 (Reuters) - Pfizer (PFE.N), opens new tab and Arvinas ... whose cancer progressed despite prior treatment, including hormone-based therapy. The data means that use of the drug, expected ...